Insilico says its AI-designed lung drug lowered biological age markers in a 42-patient trial
Covered by 2 sources
Read full post
Insilico Medicine's AI-designed drug rentosertib showed signs of lowering biological age markers in a 42-patient idiopathic pulmonary fibrosis trial, suggesting patients appeared 2.7 to 3.5 years biologically younger. The analysis used six independent ageing clocks on proteomic data but cannot yet confirm if the effect is due to slowed ageing or lung improvement.
